Prandin (repaglinide), a new oral hypoglycemic for type 2 diabetes

May 1998

You'll soon see Prandin (repaglinide), a new oral hypoglycemicfor type 2 diabetes...co-marketed by Novo Nordisk and Schering.

It's approved for monotherapy...and for use with metformin(Glucophage). It's also being tested with troglitazone (Rezulin).

Prandin is the first drug in a new class...the meglitinides.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote